Načítá se...
预测贝伐珠单抗抗肿瘤治疗效果的生物学标记物
Bevacizumab, the monoclonal antibody of vascular endothelial growth factor (VEGF) has been applied to the therapy of several neoplasms, but an appropriate biomarker to predict the efficacy has not been found. Tose markers can originate from peripheral circulation, tumor tissue and genes. Some resear...
Uloženo v:
| Vydáno v: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
中国肺癌杂志编辑部
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000279/ https://ncbi.nlm.nih.gov/pubmed/21762631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.08 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|